SERUM BIOMARKERS FACILITATE THE RECOGNITION OF EARLY STAGE CANCER AND MAY GUIDE THE SELECTION OF SURGICAL CANDIDATES (Gianfranco Buccheri et al.)

^{Pubblicato in The Journal of Thoracic and Cardiovascular Surgery 2001; 122: 891-899}

IMPORTANCE OF WEIGHT LOSS DEFINITION IN THE PROGNOSTIC EVALUATION OF NON-SMALL CELL LUNG CANCER (Gianfranco Buccheri et al.)

^{Pubblicato in  Lung Cancer 2001; 34: 433-440}

PROGNOSTIC SIGNIFICANCE OF BLOOD COAGULATION TESTS IN LUNG CANCER (Domenico Ferrigno et al.)

^{Pubblicato in  Eur.Resp.J. 2001; 17:667-673}

OVERVIEW ON SERUM TUMOR MARKERS OF CYTOKERATIN ORIGIN (Gianfranco Buccheri)

^{Pubblicato in Expert Rev. Mol Diagn. 2001, 1 (3), 89-96}

NUTRITIONAL STATUS ASSESSMENT OF PATIENTS WITH LUNG CANCER (Domenico Ferrigno et al.)

Pubblicato in Support Care Cancer 2001; 9, 522-527

^99mTc-TETROFOSMIN SCIENTIGRAPHY IN LUNG CANCER STAGING AND FOLLOW-UP EVALUATIONS (Gianfranco Buccheri et al.)

^{Pubblicato in Cancer 2002; 94:1796-1807}

LUNG TUMOUR MARKERS TPA AND CA125: A COMPARISON STUDY (Gianfranco Buccheri et al.)

PREOPERATIVE MEASUREMENTS OF CARCINOEMBRYONIC ANTIGEN MAY PREDICT EARLY RECURRENCE IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (Gianfranco Buccheri et al.)

Pubblicato in Annals of Thoracic Surgery 2003; 75:973-980

CLINICAL EQUIVALENCE OF TWO CYTOKERATIN MARKERS IN LUNG CANCER: a study of TPA and Cyfra 21-1 (Gianfranco Buccheri et al.)

Pubblicato in CHEST  2003; 124:622-632

D-DIMER PLASMA LEVELS IN LUNG CANCER: CLINICAL AND PROGNOSTIC SIGNIFICANCE (Gianfranco Buccheri et al.)

Pubblicato in Cancer 2003; 97:3044-3052

Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC) (Domenico Ferrigno et al.)

Lung cancer in North-West Italy: demographic and clinical trends in a hospital-based population of 1277 patients (Gianfranco Buccheri et al.)

Familial and personal history of cancer in bronchogenic carcinoma--frequency and clinical implications (Gianfranco Buccheri et al.)

Prognostic factors in NSCLC (Gianfranco Buccheri et al.)

Prognostic factors of small cell lung cancer (Gianfranco Buccheri et al.)

Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients (Domenico Ferrigno et al.)

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients (Jean-Louis Pujol et al.)

Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin (Gianfranco Buccheri et al.)

Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC) (Domenico Ferrigno et al.)

Lung cancer: clinical presentation and specialist referral time (Gianfranco Buccheri et al.)

Cuneo Lung Cancer Study Group - The only Italian organization dedicated SOLELY to the study of  lung cancer -  L'unica organizzazione italiana ESCLUSIVAMENTE  dedicata alla studio del cancro del polmone.

1st February 2005 / © 2005-2006  Cuneo Lung Cancer Study Group (CuLCaSG),  http://www.culcasg.org , info@culcasg.org  Tel. (+39 ) 0171- 616733 (Mon./Lun.- Fri./Ven. 9 a.m.- 4 p.m.),  Fax. (+39) 0171-616728.  Address/Indirizzo: c/o Ospedale A. Carle, I-12100 Cuneo, Italia.  First draft (prima realizzazione): 14/01/97; latest version (ultimo  aggiornamento): 08/11/2007.

A.Carle Hospital, the CuLCaSG site -  L'ospedale Carle di Cuneo, sede del gruppo

Le informazioni contenute in questo sito NON possono sostituire il lavoro del proprio medico. Approfondite con lui ogni informazione che avrete ottenuto attraverso la visita di questo sito.   I nostri medici rimangono a vostra disposizione per un  secondo parere.